Aptuit and Aegerion Pharmaceuticals have signed a long-term supply agreement for commercial quantities of the API lomitapide, Aegerion’s orphan drug targeted for the treatment of a rare disease caused by a genetic disorder.   The drug received NDA approval in December of 2012 and is expected to be launched shortly. Aptuit established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registrat...